Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05409131 for Type 1 Diabetes is completed. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Omnipod 5 System Compared to Pump Therapy 196
Clinical Trial NCT05409131 was an interventional study for Type 1 Diabetes that is now completed. The study started on 7 July 2022, with plans to enroll 196 participants. Led by Insulet Corporation, the expected completion date was 10 January 2025. The latest data from ClinicalTrials.gov was last updated on 16 September 2025.
Brief Summary
Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 90-day outpatient phase where subjects will either use the Omnipod 5 system or continue to use their personal insulin pump with the study provided continuous glucose monitoring system.
Participants in France will be offered an optional extension of 12 months of Omnipod 5...
Show MoreDetailed Description
This is an outpatient study that consists of two phases, Phase 1 and Phase 2. There will be approximately 8 study visits conducted in person or via telehealth.
Phase 1 is a 14-day period to collect baseline sensor and insulin data where subjects will manage their diabetes at home per their usual routine using the study continuous glucose monitoring system.
Phase 2 is a 90-day period where subjects will be randomize...
Show MoreOfficial Title
Efficacy and Safety of the Omnipod 5 System Compared to Pump Therapy in the Treatment of Type 1 Diabetes: a Randomized, Parallel-group Clinical Trial
Conditions
Type 1 DiabetesOther Study IDs
- OP5-003 (G6 CSII)
NCT ID Number
Start Date (Actual)
2022-07-07
Last Update Posted
2025-09-16
Completion Date (Estimated)
2025-01-10
Enrollment (Estimated)
196
Study Type
Interventional
PHASE
N/A
Status
Completed
Keywords
T1D
Omnipod
Automated Insulin Delivery
Omnipod
Automated Insulin Delivery
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Active ComparatorIntervention Arm Omnipod 5 System with Dexcom G6 continuous glucose monitoring system | Omnipod 5 System Omnipod 5 System automates insulin delivery based on information received from the continuous glucose monitoring system every 5 minutes. |
No InterventionControl Arm Participant's current insulin pump with Dexcom G6 continuous glucose monitoring system | N/A |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Percent of Time in Range 70-180 mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing intervention group with control group during the 13-week study phase |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Percent of Time <54 mg/dL (Non-inferiority) | Glucose metric from study continuous glucose monitoring system | Comparing intervention group with control group at the end of the 13-week study phase |
Percent of Time >180 mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing intervention group with control group at the end of the 13-week study phase |
Mean Glucose | Glucose metric from study continuous glucose monitoring system | Comparing intervention group with control group at the end of the 13-week study phase |
Change in HbA1c | Measures device effectiveness | Baseline compared to end of study visit (Day -30 to Day 90) |
Percent of Time <70 mg/dL | Glucose metric from study continuous glucose monitoring system | Comparing intervention group with control group at the end of the 13-week study phase |
Change in Diabetes Distress Scale for Adults With Type 1 Diabetes (T1-DDS) Total Score | A questionnaire that measures seven critical dimensions of distress (28-item scale with 6 choices that range from 1 (Not a Problem) to 6 (A Very Serious Problem)). The total score can range from 1 to 6, with a lower score indicating a better outcome. | Baseline compared to end of study visit (Day -14 to Day 90) |
Change in Hypoglycemic Confidence Scale (HCS) Total Score | A questionnaire that examines the degree to which people with diabetes feel able, secure, and comfortable regarding their ability to stay safe from hypoglycemic-related problems (9-item scale with 4 choices that range from 1 (Not Confident At All) to 4 (Very Confident)). The total score can range from 1 to 4, with a higher score indicating a better outcome. | Baseline compared to end of study visit (Day -14 to Day 90) |
Change in Diabetes Quality of Life (DQOL)-Brief Total Score | A questionnaire that assesses the relative burden of an intensive diabetes treatment regimen (15-item scale with 5 choices that range from 1 (Very Dissatisfied/All the Time) to 5 (Very Satisfied/Never)). The total score can range from 1 to 5, with a higher score indicating a better outcome. | Baseline compared to end of study visit (Day -14 to Day 90) |
Proportion of Participants With T1-DDS MCID After 13 Weeks | Proportion of participants achieving a minimal clinically important difference (MCID) of ≥ 0.19 points (improvement) on the T1-DDS questionnaire total score at 13 weeks compared between treatment groups | Comparing intervention group with control group at the end of the 13-week study phase |
Proportion of Participants With DQOL-brief Clinically Meaningful Improvement After 13 Weeks | Proportion of participants achieving a clinically meaningful improvement in the DQOL-brief total score after 13 weeks | Comparing intervention group with control group at the end of the 13-week study phase |
Proportion of Participants With HCS Mean Score ≥ 3 After 13 Weeks | Secondary Effectiveness Endpoint of Proportion of Participants with HCS Mean Score ≥ 3 After 13 Weeks OP5 | Comparing intervention group with control group at the end of the 13-week study phase |
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Age at time of consent 18-70 years of age
- Diagnosed with type 1 diabetes for at least 1 year. Diagnosis is based on investigator's clinical judgment.
- On pump therapy for ≥ 3 months prior to screening and familiar with pump therapy concepts such as basal and bolus insulin delivery, and carbohydrate counting. Participants using automated insulin delivery (AID) devices, including devices with predictive low glucose suspend (PLGS), in the 3 months prior to screening, will be excluded from participating.
- A1C 7.0-11.0% by point-of-care taken at screening visit
- Willing to use and obtain U-100 insulin: (either insulin aspart (Novolog, NovoRapid), or insulin lispro (Humalog, Admelog)), as the primary insulin treatment
- Must have a smartphone that supports the Dexcom app download and participants must be willing to use the app throughout the study
- Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol
- Willing to wear the system continuously throughout the study
- Willing and able to sign the Informed Consent Form (ICF)
- Any medical condition, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal failure, eating disorders, or other conditions which in the opinion of the investigator, would put the participant at an unacceptable safety risk
- History of severe hypoglycemia in the past 6 months
- History of diabetic ketoacidosis (DKA) in the past 6 months, unrelated to an intercurrent illness or infusion set failure
- Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the investigator's opinion could interfere with determination of HbA1C.
- Currently on systemic steroids or intends to receive systemic steroid treatment during study participation, including stable treatment for adrenal insufficiency. Inhaled, ophthalmic, topical, joint injection, and other locally applied steroids are allowed.
- Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement
- Use of non-insulin anti-hyperglycemic medication other than metformin, in the 12 weeks prior to the Baseline Visit. Participants taking metformin should remain on a steady dose during study participation.
- Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner)
- Participation in another clinical study using an investigational drug or device within 30-days or 5 half-lives (whichever is longer) prior to screening, or intends to participate in any other study during this study period
- Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator's clinical judgment
- Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member of any of the aforementioned
Insulet CorporationNo contact data.
14 Study Locations in 2 Countries
California
Stanford University School of Medicine, Palo Alto, California, 94304, United States
Sansum Diabetes Research Institute, Santa Barbara, California, 93105, United States
Colorado
University of Colorado Denver, Denver, Colorado, 80045, United States
Georgia
Atlanta Diabetes, Atlanta, Georgia, 30318, United States
Illinois
Northwestern University, Evanston, Illinois, 60208, United States
Massachusetts
Joslin Diabetes Center, Boston, Massachusetts, 02215, United States
New York
State University of New York, Upstate Medical University, Syracuse, New York, 13244, United States
Texas
Diabetes & Glandular Disease Clinic, P.A. (DGD Clinic), San Antonio, Texas, 78229, United States
Virginia
University of Virginia, Charlottesville, Virginia, 22903, United States
Washington
University of Washington, Seattle, Washington, 98109, United States
Hopital Sud-Francilien, Corbeil-Essonnes, France
Hospices Civils de Lyon - Centre du diabete Diab-eCare, Lyon, France
CHRU de Montpellier, Hopital Lapeyronie - Departement d'endocrinologie, Diabete, Nutrition, Montpellier, France
Hopital Lariboisiere - Centre Universitaire du Diabete et de ses Complications, Paris, France